Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Core Viewpoint - Glancy Prongay Wolke & Rotter LLP has initiated an investigation on behalf of ADMA Biologics, Inc. investors regarding potential violations of federal securities laws by the company [1] Group 1 - The investigation is aimed at ADMA Biologics, Inc. (NASDAQ: ADMA) and concerns possible legal claims for investors who have incurred losses [1] - The law firm is reaching out to investors who lost money on ADMA Biologics, indicating a focus on recovering those losses through potential claims [1]